Redirecting the Immune Microenvironment in Acute Myeloid Leukemia

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Acute myeloid leukemia (AML) arises in a complex microenvironment that can promote leukemogenesis.
• Relapsed and refractory AML presents significant treatment challenges, especially after prior therapies.
• Hematopoietic stem cell transplantation (HSCT) is the primary cure for R/R AML, but toxicities limit its use.

Purpose of the Study:

• To review immunological dysregulations in AML pathogenesis and progression.
• To highlight therapeutic targets for overcoming the immunosuppressive AML microenvironment.
• To identify innovative immunotherapeutic strategies for AML.

Main Methods:

• Literature review focusing on immunological aspects of AML.
• Analysis of immune evasion strategies employed by AML blasts.
• Evaluation of the clinical impact of the immune-privileged AML microenvironment.

Main Results:

• The AML microenvironment can promote leukemogenesis and immune evasion.
• Existing treatments like HSCT have limitations due to toxicity.
• Immunotherapy holds promise but requires enhanced specificity and reduced toxicity.

Conclusions:

• Targeting immune evasion and the microenvironment is crucial for effective AML immunotherapy.
• Further research into novel immunotherapeutic approaches is warranted.
• Engineering immunotherapies to be more specific and less toxic can improve outcomes for R/R AML patients.